Identification of poor responders to erythropoietin among children undergoing hemodialysis

Wacharee Seeherunvong, Liliana Rubio, Carolyn Abitbol, Brenda Montané, Jose Strauss, Rosa Diaz, Gaston E Zilleruelo

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objectives: To identify the factors determining a high recombinant human erythropoietin (rHuEPO) dose requirement and associated side effects in children undergoing hemodialysis. Study design: We retrospectively analyzed the clinical data of 23 children (aged 5-20 years) undergoing long-term hemodialysis. All subjects received intravenous rHuEPO to maintain hemoglobin levels ≥10 g/dL and had iron supplement. Subjects were divided into 2 groups: those receiving high-dose rHuEPO (≥450 U/kg/wk) and those receiving an average dose (<450 U/kg/wk). We compared the specific variables between both groups by using Mann-Whitney, Fisher exact, and linear regression tests; a P value <.05 was considered significant. Results: Four of 23 subjects (17%) received high-dose rHuEPO despite iron repletion. These subjects were small and young and had frequent bacterial infections, high ferritin levels, and severe hyperparathyroidism. Two patients with human immunodeficiency virus infection required high-dose rHuEPO. The main adverse effect of high-dose rHuEPO was an increase in the heparin requirement during hemodialysis. Conclusions: Age, body weight, inflammatory status, and severity of hyperparathyroidism should be taken into account when adjusting rHuEPO dose for children undergoing hemodialysis. Furthermore, we suggest that high rHuEPO doses are related to an increase in the heparin requirement in these children.

Original languageEnglish
Pages (from-to)710-714
Number of pages5
JournalJournal of Pediatrics
Volume138
Issue number5
DOIs
StatePublished - May 20 2001

Fingerprint

Erythropoietin
Renal Dialysis
Hyperparathyroidism
Heparin
Iron
Virus Diseases
Ferritins
Bacterial Infections
Linear Models
Hemoglobins
Body Weight
HIV

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Identification of poor responders to erythropoietin among children undergoing hemodialysis. / Seeherunvong, Wacharee; Rubio, Liliana; Abitbol, Carolyn; Montané, Brenda; Strauss, Jose; Diaz, Rosa; Zilleruelo, Gaston E.

In: Journal of Pediatrics, Vol. 138, No. 5, 20.05.2001, p. 710-714.

Research output: Contribution to journalArticle

Seeherunvong, Wacharee ; Rubio, Liliana ; Abitbol, Carolyn ; Montané, Brenda ; Strauss, Jose ; Diaz, Rosa ; Zilleruelo, Gaston E. / Identification of poor responders to erythropoietin among children undergoing hemodialysis. In: Journal of Pediatrics. 2001 ; Vol. 138, No. 5. pp. 710-714.
@article{94ab1a2fe0314777ba433cbe5c394f46,
title = "Identification of poor responders to erythropoietin among children undergoing hemodialysis",
abstract = "Objectives: To identify the factors determining a high recombinant human erythropoietin (rHuEPO) dose requirement and associated side effects in children undergoing hemodialysis. Study design: We retrospectively analyzed the clinical data of 23 children (aged 5-20 years) undergoing long-term hemodialysis. All subjects received intravenous rHuEPO to maintain hemoglobin levels ≥10 g/dL and had iron supplement. Subjects were divided into 2 groups: those receiving high-dose rHuEPO (≥450 U/kg/wk) and those receiving an average dose (<450 U/kg/wk). We compared the specific variables between both groups by using Mann-Whitney, Fisher exact, and linear regression tests; a P value <.05 was considered significant. Results: Four of 23 subjects (17{\%}) received high-dose rHuEPO despite iron repletion. These subjects were small and young and had frequent bacterial infections, high ferritin levels, and severe hyperparathyroidism. Two patients with human immunodeficiency virus infection required high-dose rHuEPO. The main adverse effect of high-dose rHuEPO was an increase in the heparin requirement during hemodialysis. Conclusions: Age, body weight, inflammatory status, and severity of hyperparathyroidism should be taken into account when adjusting rHuEPO dose for children undergoing hemodialysis. Furthermore, we suggest that high rHuEPO doses are related to an increase in the heparin requirement in these children.",
author = "Wacharee Seeherunvong and Liliana Rubio and Carolyn Abitbol and Brenda Montan{\'e} and Jose Strauss and Rosa Diaz and Zilleruelo, {Gaston E}",
year = "2001",
month = "5",
day = "20",
doi = "10.1067/mpd.2001.112246",
language = "English",
volume = "138",
pages = "710--714",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Identification of poor responders to erythropoietin among children undergoing hemodialysis

AU - Seeherunvong, Wacharee

AU - Rubio, Liliana

AU - Abitbol, Carolyn

AU - Montané, Brenda

AU - Strauss, Jose

AU - Diaz, Rosa

AU - Zilleruelo, Gaston E

PY - 2001/5/20

Y1 - 2001/5/20

N2 - Objectives: To identify the factors determining a high recombinant human erythropoietin (rHuEPO) dose requirement and associated side effects in children undergoing hemodialysis. Study design: We retrospectively analyzed the clinical data of 23 children (aged 5-20 years) undergoing long-term hemodialysis. All subjects received intravenous rHuEPO to maintain hemoglobin levels ≥10 g/dL and had iron supplement. Subjects were divided into 2 groups: those receiving high-dose rHuEPO (≥450 U/kg/wk) and those receiving an average dose (<450 U/kg/wk). We compared the specific variables between both groups by using Mann-Whitney, Fisher exact, and linear regression tests; a P value <.05 was considered significant. Results: Four of 23 subjects (17%) received high-dose rHuEPO despite iron repletion. These subjects were small and young and had frequent bacterial infections, high ferritin levels, and severe hyperparathyroidism. Two patients with human immunodeficiency virus infection required high-dose rHuEPO. The main adverse effect of high-dose rHuEPO was an increase in the heparin requirement during hemodialysis. Conclusions: Age, body weight, inflammatory status, and severity of hyperparathyroidism should be taken into account when adjusting rHuEPO dose for children undergoing hemodialysis. Furthermore, we suggest that high rHuEPO doses are related to an increase in the heparin requirement in these children.

AB - Objectives: To identify the factors determining a high recombinant human erythropoietin (rHuEPO) dose requirement and associated side effects in children undergoing hemodialysis. Study design: We retrospectively analyzed the clinical data of 23 children (aged 5-20 years) undergoing long-term hemodialysis. All subjects received intravenous rHuEPO to maintain hemoglobin levels ≥10 g/dL and had iron supplement. Subjects were divided into 2 groups: those receiving high-dose rHuEPO (≥450 U/kg/wk) and those receiving an average dose (<450 U/kg/wk). We compared the specific variables between both groups by using Mann-Whitney, Fisher exact, and linear regression tests; a P value <.05 was considered significant. Results: Four of 23 subjects (17%) received high-dose rHuEPO despite iron repletion. These subjects were small and young and had frequent bacterial infections, high ferritin levels, and severe hyperparathyroidism. Two patients with human immunodeficiency virus infection required high-dose rHuEPO. The main adverse effect of high-dose rHuEPO was an increase in the heparin requirement during hemodialysis. Conclusions: Age, body weight, inflammatory status, and severity of hyperparathyroidism should be taken into account when adjusting rHuEPO dose for children undergoing hemodialysis. Furthermore, we suggest that high rHuEPO doses are related to an increase in the heparin requirement in these children.

UR - http://www.scopus.com/inward/record.url?scp=0035025315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035025315&partnerID=8YFLogxK

U2 - 10.1067/mpd.2001.112246

DO - 10.1067/mpd.2001.112246

M3 - Article

VL - 138

SP - 710

EP - 714

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 5

ER -